Cladribine injection and Estradiol and norgestimate
Determining the interaction of Cladribine injection and Estradiol and norgestimate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives. MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. Cerner Multum, Inc. "Australian Product Information." O 0
Professional:ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.
MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: cladribine
Brand name: Mavenclad, Leustatin
Synonyms: Cladribine
Generic Name: estradiol / norgestimate
Brand name: Prefest, Ortho-Prefest
Synonyms: Estradiol and Norgestimate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cladribine injection-Estradiol and progesterone
- Cladribine injection-Estradiol Gel (Divigel)
- Cladribine injection-Estradiol Gel (Elestrin)
- Cladribine injection-Estradiol Gel (EstroGel)
- Cladribine injection-Estradiol injection
- Cladribine injection-Estradiol Oral Tablets
- Estradiol and norgestimate-Cladribine Intravenous
- Estradiol and norgestimate-Cladribine Tablets
- Estradiol and norgestimate-Claforan
- Estradiol and norgestimate-Claforan in D5W
- Estradiol and norgestimate-Claravis
- Estradiol and norgestimate-Clarifoam EF